CO2018006701A2 - Formas polimórficas cristalinas del ácido obeticólico - Google Patents

Formas polimórficas cristalinas del ácido obeticólico

Info

Publication number
CO2018006701A2
CO2018006701A2 CONC2018/0006701A CO2018006701A CO2018006701A2 CO 2018006701 A2 CO2018006701 A2 CO 2018006701A2 CO 2018006701 A CO2018006701 A CO 2018006701A CO 2018006701 A2 CO2018006701 A2 CO 2018006701A2
Authority
CO
Colombia
Prior art keywords
obetolic
polymorphic forms
acid
crystalline polymorphic
obetolic acid
Prior art date
Application number
CONC2018/0006701A
Other languages
English (en)
Spanish (es)
Inventor
André Steiner
Poulsen Heidi Waenerlund
Emilie Jolibois
Melissa Rewolinski
Ralf Gross
Emma Sharp
Fiona Dubas-Fisher
Alex Eberlin
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55650649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018006701(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/979,005 external-priority patent/US9982008B2/en
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of CO2018006701A2 publication Critical patent/CO2018006701A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2018/0006701A 2015-12-22 2018-06-27 Formas polimórficas cristalinas del ácido obeticólico CO2018006701A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/979,005 US9982008B2 (en) 2012-06-19 2015-12-22 Preparation and uses of obeticholic acid
PCT/US2016/012651 WO2017111979A1 (en) 2015-12-22 2016-01-08 Polymorphic crystalline forms of obeticholic acid

Publications (1)

Publication Number Publication Date
CO2018006701A2 true CO2018006701A2 (es) 2018-07-10

Family

ID=55650649

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0006701A CO2018006701A2 (es) 2015-12-22 2018-06-27 Formas polimórficas cristalinas del ácido obeticólico

Country Status (15)

Country Link
EP (1) EP3394081A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018538331A (cg-RX-API-DMAC7.html)
KR (1) KR20180095070A (cg-RX-API-DMAC7.html)
CN (1) CN108495858A (cg-RX-API-DMAC7.html)
AU (1) AU2016375566A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018012590A2 (cg-RX-API-DMAC7.html)
CA (1) CA3009149A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018001720A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018006701A2 (cg-RX-API-DMAC7.html)
EA (1) EA201891491A1 (cg-RX-API-DMAC7.html)
IL (1) IL259998A (cg-RX-API-DMAC7.html)
MX (1) MX2018007776A (cg-RX-API-DMAC7.html)
PH (1) PH12018501318A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201805235XA (cg-RX-API-DMAC7.html)
WO (1) WO2017111979A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105801653B (zh) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
WO2018211413A1 (en) * 2017-05-15 2018-11-22 Dr. Reddy’S Laboratories Limited Solid forms of obeticholic acid and process for preparation
CN109280071A (zh) * 2017-07-19 2019-01-29 东莞东阳光药物研发有限公司 奥贝胆酸的晶型及其制备方法
CN107383139A (zh) * 2017-08-09 2017-11-24 杭州和泽医药科技有限公司 一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法
CZ31099U1 (cs) * 2017-09-05 2017-10-17 Zentiva, K.S. Krystalické formy (3a,5B,6a,7a)-6-ethyl-3,7- dihydroxycholan-24-ové kyseliny
CN109485687A (zh) * 2017-09-12 2019-03-19 成都弘达药业有限公司 奥贝胆酸的晶型j及其制备方法
WO2019106043A1 (en) 2017-11-29 2019-06-06 Hexal Ag Pharmaceutical composition comprising obeticholic acid
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN113264972B (zh) * 2020-02-14 2024-07-12 四川科伦药物研究院有限公司 一种制备奥贝胆酸的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
EA201990211A1 (ru) * 2012-06-19 2019-06-28 Интерсепт Фармасьютикалз, Инк. Получение, применение и твердые формы обетихолевой кислоты
CN106459136B (zh) * 2014-09-28 2018-06-26 江苏盛迪医药有限公司 一种奥贝胆酸的制备方法
PL3221332T3 (pl) * 2014-11-19 2019-10-31 Nzp Uk Ltd Steroidy, 5.beta.-6-alkilo-7-hydroksy-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
BR112017010319B1 (pt) * 2014-11-19 2023-04-11 NZP UK Limited Esteroides 6-alquil-7-hidróxi-4-en-3-ona e processo para a preparação dos mesmos
WO2016079520A1 (en) * 2014-11-19 2016-05-26 Dextra Laboratories Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
DK3221333T3 (da) * 2014-11-19 2019-09-30 Nzp Uk Ltd 6-alfa-alkyl-3,7-dionsteroider som mellemprodukter til fremstilling af steroide FXR-modulatorer

Also Published As

Publication number Publication date
BR112018012590A2 (pt) 2018-12-04
JP2018538331A (ja) 2018-12-27
EP3394081A1 (en) 2018-10-31
IL259998A (en) 2018-07-31
AU2016375566A1 (en) 2018-07-05
WO2017111979A1 (en) 2017-06-29
CN108495858A (zh) 2018-09-04
PH12018501318A1 (en) 2019-02-18
MX2018007776A (es) 2018-08-09
EA201891491A1 (ru) 2018-11-30
KR20180095070A (ko) 2018-08-24
SG11201805235XA (en) 2018-07-30
CL2018001720A1 (es) 2018-08-10
CA3009149A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
CO2018006701A2 (es) Formas polimórficas cristalinas del ácido obeticólico
CO2017001884A2 (es) Polimorfos de selinexor
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
MX382671B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
CL2014003455A1 (es) Método para inhibir activación del complemento dependiente de masp-3 y, opcionalmente masp-1 y masp-2, para el tratamiento de diversas enfermedades y trastornos.
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
AR108800A1 (es) Purificación de anticuerpos multiespecíficos
GT201700146A (es) Compuestos de triazolopirimidina y usos de los mismos
MX364559B (es) Metodos de purificacion de cannabinoides, composiciones y kits de los mismos.
ECSP17046848A (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y osteoartritis
CL2018000914A1 (es) Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-en-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular
CL2014003475A1 (es) Forma c cristalina de acido obeticolico; proceso de preparacion de la forma 1 de acido obeticolico a partir de la forma c cristalina; composicion farmaceutica que comprende a una forma cristalina de acido obeticolico, util para el tratamiento o prevencion de una enfermedad hepatica colestasica, hepatopatia alcoholica y enfermedades cardiovasculares tal como aterosclerosis, entre otras.
DOP2017000013A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CL2018000835A1 (es) Prevención, tratamiento y reversión de la enfermedad usando una cantidad terapeuticamente efectiva de ácidos grasos activados
MX2019009783A (es) Metodo para fabricar una barra que comprende antitranspirante.
CO6850301A1 (es) Composiciones y métodos para mejorar la calidad del esperma procesado
AR086586A1 (es) Forma cristalina de ciclosporina a, metodos de preparacion y metodos para utilizar la misma
BR112016020260A2 (pt) uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
LT3200817T (lt) Būdas ir kompozicija, skirti sustiprintų priešuždegiminių/antikatabolinių ir regeneracinių agentų gamybai iš autologinio kraujo
CO2017000950A2 (es) Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos
CL2014000484A1 (es) Compuestos derivados del acido pirrolidin-3-il-acetico; composicion farmaceutica que los comprende y uso en el tratamiento de la enfermedad inflamatoria del intestino.
UY36385A (es) Piperidinilpirazolopirimidinonas y utilización de las mismas
DK3305754T3 (da) Fremgangsmåder til fremstilling af højumættet fedtsyre med høj renhed med højt udbytte